Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 4Gastrointestinal 2NET 1

Conditions

Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Colonic Neoplasms 94Neoplasm Metastasis 60Esophageal Neoplasms 57Neoplasms 40Biliary Tract Neoplasms 39Cholangiocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Breast Neoplasms 28Adenocarcinoma 22Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Gastrointestinal Neoplasms 18Liver Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Carcinoma, Non-Small-Cell Lung 12Anus Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Digestive System Neoplasms 7Carcinoma 7Advanced Gastric Cancer 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Klatskin Tumor 6

Interventions

Trastuzumab 2Temozolomide 2Capecitabine 2tipifarnib 1Oxaliplatin 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Floxuridine 1Fentanyl 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrinoma × Capecitabine × Gastrointestinal × Clear all
NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Stanford University

Phase 2 Completed
20 enrolled 15 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Columbia University

Phase 2 Completed
41 enrolled 9 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡